BRPI0908849A2 - Composto e composições como c-kit e inibidores de pdgfr quinase - Google Patents
Composto e composições como c-kit e inibidores de pdgfr quinaseInfo
- Publication number
- BRPI0908849A2 BRPI0908849A2 BRPI0908849-0A BRPI0908849A BRPI0908849A2 BR PI0908849 A2 BRPI0908849 A2 BR PI0908849A2 BR PI0908849 A BRPI0908849 A BR PI0908849A BR PI0908849 A2 BRPI0908849 A2 BR PI0908849A2
- Authority
- BR
- Brazil
- Prior art keywords
- kit
- compositions
- compound
- kinase inhibitors
- pdgfr kinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3091208P | 2008-02-22 | 2008-02-22 | |
PCT/US2009/034778 WO2009105712A1 (en) | 2008-02-22 | 2009-02-20 | Heterocyclic compounds and compositions as c-kit and pdgfr kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0908849A2 true BRPI0908849A2 (pt) | 2015-08-25 |
Family
ID=40577860
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0908849-0A BRPI0908849A2 (pt) | 2008-02-22 | 2009-02-20 | Composto e composições como c-kit e inibidores de pdgfr quinase |
Country Status (17)
Country | Link |
---|---|
US (1) | US8278452B2 (pt) |
EP (1) | EP2252612B1 (pt) |
JP (1) | JP5230755B2 (pt) |
KR (1) | KR101216323B1 (pt) |
CN (1) | CN102083828B (pt) |
AR (1) | AR070469A1 (pt) |
AT (1) | ATE551342T1 (pt) |
AU (1) | AU2009217356B2 (pt) |
BR (1) | BRPI0908849A2 (pt) |
CA (1) | CA2714700C (pt) |
CL (1) | CL2009000400A1 (pt) |
EA (1) | EA018551B1 (pt) |
ES (1) | ES2383331T3 (pt) |
MX (1) | MX2010009207A (pt) |
PE (1) | PE20091492A1 (pt) |
TW (1) | TW200940538A (pt) |
WO (1) | WO2009105712A1 (pt) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011049625A1 (en) | 2009-10-20 | 2011-04-28 | Mansour Samadpour | Method for aflatoxin screening of products |
MX352661B (es) | 2009-11-05 | 2017-12-04 | Rhizen Pharmaceuticals S A Star | Moduladores novedosos de benzopiran cinasa. |
TWI510487B (zh) | 2010-04-21 | 2015-12-01 | Plexxikon Inc | 用於激酶調節的化合物和方法及其適應症 |
JP5580492B2 (ja) * | 2011-03-01 | 2014-08-27 | エヌファルマコン,エルエルシー | N−(4−メトキシフェニル)−1−フェニル−1h−ピラゾール−3−アミンおよび関連化合物の使用 |
PL2705029T4 (pl) | 2011-05-04 | 2019-04-30 | Rhizen Pharmaceuticals S.A. | Nowe związki jako modulatory kinaz białkowych |
CN103889993B (zh) * | 2011-09-19 | 2017-05-31 | 吉奇亚公司 | 修饰的肌酸化合物 |
CA3107640A1 (en) | 2011-12-22 | 2013-06-27 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof and their use in ameliorating or treating a disease or condition associated with viral infections |
USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
CN104395330B (zh) | 2012-05-25 | 2018-03-13 | 爱尔兰詹森科学公司 | 尿嘧啶基螺氧杂环丁烷核苷 |
EP3366293B1 (en) * | 2012-06-07 | 2020-03-11 | Deciphera Pharmaceuticals, LLC | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
PL2870157T3 (pl) | 2012-07-04 | 2018-01-31 | Rhizen Pharmaceuticals S A | Selektywne inhibitory pi3k delta |
US9243022B2 (en) | 2012-12-21 | 2016-01-26 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
PT3363790T (pt) | 2013-09-06 | 2020-05-06 | Aurigene Discovery Tech Ltd | Derivados 1,2,4-oxadiazoles como imunomoduladores |
CN104458674A (zh) * | 2013-09-12 | 2015-03-25 | 中国药科大学 | 一种筛选血管内皮生长因子1激酶抑制剂高通量筛选方法 |
CN104458675A (zh) * | 2013-09-12 | 2015-03-25 | 中国药科大学 | 一种筛选干细胞因子受体激酶抑制剂高通量筛选方法 |
US9862743B2 (en) | 2013-10-11 | 2018-01-09 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
ES2907988T3 (es) | 2015-03-10 | 2022-04-27 | Aurigene Discovery Tech Ltd | Compuestos de 1,2,4-oxadiazol y tiadiazol como inmunomoduladores |
CA2979161A1 (en) * | 2015-03-10 | 2016-09-15 | Aurigene Discovery Technologies Limited | 3-substituted-1,2,4-oxadiazole and thiadiazole compounds as immunomodulators |
ES2898882T3 (es) * | 2016-01-11 | 2022-03-09 | Merck Patent Gmbh | Derivados de quinolin-2-ona |
WO2019061324A1 (en) | 2017-09-29 | 2019-04-04 | Curis Inc. | CRYSTALLINE FORMS OF IMMUNOMODULATORS |
JP2020536872A (ja) | 2017-10-11 | 2020-12-17 | オーリジーン ディスカバリー テクノロジーズ リミテッドAurigene Discovery Technologies Limited | 3−置換1,2,4−オキサジアゾールの結晶形態 |
BR112020008537A2 (pt) | 2017-11-03 | 2020-10-06 | Aurigene Discovery Technologies Limited | inibidores duplos de vias da tim-3 e da pd-1 |
WO2019087092A1 (en) | 2017-11-06 | 2019-05-09 | Aurigene Discovery Technologies Limited | Conjoint therapies for immunomodulation |
WO2019164996A1 (en) | 2018-02-21 | 2019-08-29 | Southern Research Institute | 2-aminoaryl-5-aryloxazole analogs for the treatment of neurodegenerative diseases |
WO2019222497A1 (en) | 2018-05-17 | 2019-11-21 | Southern Research Institute | 2,5-aryl-thiazole analogs for the treatment of neurodegenerative diseases |
AU2020242287A1 (en) | 2019-03-21 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
US10927111B2 (en) | 2019-05-03 | 2021-02-23 | Kinnate Biopharma Inc. | Inhibitors of RAF kinases |
KR20220045189A (ko) | 2019-08-12 | 2022-04-12 | 데시페라 파마슈티칼스, 엘엘씨. | 위장관 기질 종양을 치료하는 방법 |
WO2021030405A1 (en) | 2019-08-12 | 2021-02-18 | Deciphera Pharmaceuticals, Llc | Ripretinib for treating gastrointestinal stromal tumors |
TW202128680A (zh) | 2019-10-24 | 2021-08-01 | 美商奇奈特生物製藥公司 | Raf激酶抑制劑 |
WO2021089791A1 (en) | 2019-11-08 | 2021-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
EP4084779A1 (en) | 2019-12-30 | 2022-11-09 | Deciphera Pharmaceuticals, LLC | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea |
CA3163053A1 (en) | 2019-12-30 | 2021-07-08 | Michael D. Kaufman | Amorphous kinase inhibitor formulations and methods of use thereof |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
WO2022060996A1 (en) | 2020-09-18 | 2022-03-24 | Kinnate Biopharma Inc. | Inhibitors of raf kinases |
WO2022081469A1 (en) | 2020-10-12 | 2022-04-21 | Kinnate Biopharma Inc. | Inhibitors of raf kinases |
CA3216104A1 (en) | 2021-04-23 | 2022-10-27 | Aleksandra Franovic | Treatment of cancer with a raf inhibitor |
CN113662938B (zh) * | 2021-09-26 | 2022-08-16 | 广西科技大学 | 一种胺类衍生物在制备抗肿瘤药物组合物中的应用 |
US11814384B2 (en) | 2022-02-03 | 2023-11-14 | Kinnate Biopharma Inc. | Inhibtors of Raf kinases |
US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA985870B (en) | 1997-07-15 | 1999-01-27 | Dainippon Pharmaceutical Co | 5-substituted-3-oxadiazolyl-1, 6-naphthyridin-2(1H)-one derivatives |
US6150359A (en) | 1997-08-20 | 2000-11-21 | Warner-Lambert Company | Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation |
US6822097B1 (en) | 2002-02-07 | 2004-11-23 | Amgen, Inc. | Compounds and methods of uses |
PA8577501A1 (es) | 2002-07-25 | 2004-02-07 | Warner Lambert Co | Inhibidores de quinasas |
CN1863774B (zh) * | 2003-10-08 | 2010-12-15 | Irm责任有限公司 | 用作蛋白激酶抑制剂的化合物和组合物 |
US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
GT200500321A (es) * | 2004-11-09 | 2006-09-04 | Compuestos y composiciones como inhibidores de proteina kinase. | |
US20090312349A1 (en) * | 2004-12-23 | 2009-12-17 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
EP2942349A1 (en) * | 2004-12-23 | 2015-11-11 | Deciphera Pharmaceuticals, LLC | Enzyme modulators and treatments |
JP2009504665A (ja) * | 2005-08-09 | 2009-02-05 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤としての化合物および組成物 |
NZ566862A (en) | 2005-09-27 | 2010-12-24 | Irm Llc | Diarylamine-containing compounds and compositions, and their use as modulators of C-kit receptors |
US20090312321A1 (en) * | 2006-05-15 | 2009-12-17 | Irm Llc | Compositions and methods for fgf receptor kinases inhibitors |
US8188113B2 (en) | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
US7897762B2 (en) * | 2006-09-14 | 2011-03-01 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of proliferative diseases |
BRPI0718162A2 (pt) * | 2006-10-20 | 2013-11-26 | Irm Llc | Composição e métodos para modulara os receptores c-kit e pdgfr |
CA2686382C (en) | 2007-05-04 | 2013-09-17 | Irm Llc | Phenylaminopyrimidine derivatives and compositions thereof as c-kit and pdgfr kinase inhibitors |
ES2381318T3 (es) | 2007-05-04 | 2012-05-25 | Irm Llc | Derivados de pirimidina y composiciones útiles como inhibidores de cinasas C-KIT y PDGFR |
-
2009
- 2009-02-20 EP EP09711557A patent/EP2252612B1/en not_active Not-in-force
- 2009-02-20 JP JP2010547818A patent/JP5230755B2/ja not_active Expired - Fee Related
- 2009-02-20 AT AT09711557T patent/ATE551342T1/de active
- 2009-02-20 WO PCT/US2009/034778 patent/WO2009105712A1/en active Application Filing
- 2009-02-20 MX MX2010009207A patent/MX2010009207A/es active IP Right Grant
- 2009-02-20 ES ES09711557T patent/ES2383331T3/es active Active
- 2009-02-20 CN CN2009801139589A patent/CN102083828B/zh not_active Expired - Fee Related
- 2009-02-20 US US12/918,801 patent/US8278452B2/en not_active Expired - Fee Related
- 2009-02-20 PE PE2009000257A patent/PE20091492A1/es not_active Application Discontinuation
- 2009-02-20 BR BRPI0908849-0A patent/BRPI0908849A2/pt not_active IP Right Cessation
- 2009-02-20 CL CL2009000400A patent/CL2009000400A1/es unknown
- 2009-02-20 EA EA201001331A patent/EA018551B1/ru not_active IP Right Cessation
- 2009-02-20 AU AU2009217356A patent/AU2009217356B2/en not_active Ceased
- 2009-02-20 KR KR1020107021103A patent/KR101216323B1/ko not_active IP Right Cessation
- 2009-02-20 CA CA2714700A patent/CA2714700C/en not_active Expired - Fee Related
- 2009-02-23 TW TW098105719A patent/TW200940538A/zh unknown
- 2009-02-24 AR ARP090100626A patent/AR070469A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
AR070469A1 (es) | 2010-04-07 |
AU2009217356B2 (en) | 2012-05-03 |
CA2714700C (en) | 2013-07-30 |
KR101216323B1 (ko) | 2012-12-27 |
PE20091492A1 (es) | 2009-10-22 |
CN102083828B (zh) | 2013-11-13 |
EP2252612A1 (en) | 2010-11-24 |
MX2010009207A (es) | 2011-03-03 |
AU2009217356A1 (en) | 2009-08-27 |
JP2011513231A (ja) | 2011-04-28 |
EA018551B1 (ru) | 2013-08-30 |
CA2714700A1 (en) | 2009-08-27 |
US20110183997A1 (en) | 2011-07-28 |
TW200940538A (en) | 2009-10-01 |
EA201001331A1 (ru) | 2011-04-29 |
CN102083828A (zh) | 2011-06-01 |
EP2252612B1 (en) | 2012-03-28 |
ATE551342T1 (de) | 2012-04-15 |
ES2383331T3 (es) | 2012-06-20 |
JP5230755B2 (ja) | 2013-07-10 |
CL2009000400A1 (es) | 2010-09-10 |
WO2009105712A1 (en) | 2009-08-27 |
US8278452B2 (en) | 2012-10-02 |
KR20100115379A (ko) | 2010-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0908849A2 (pt) | Composto e composições como c-kit e inibidores de pdgfr quinase | |
CY2019027I1 (el) | Παραγωγα φωσφορου ως αναστολεις κινασης | |
BRPI0811516A2 (pt) | Compostos e composições como inibidores de c-kit e pdgfr cinase | |
CY2020024I2 (el) | Αναστολεiς βητα-λακταμασων | |
LTPA2019006I1 (lt) | Junginiai ir kompozicijos kaip proteinkinazės inhibitoriai | |
BRPI0912668A2 (pt) | composto e composições como inibidores de quinase | |
BRPI0914652A2 (pt) | compostos e composições como inibidores de quinase | |
BRPI0911228A2 (pt) | compostos e composições como inibidores de proteínas quinase | |
BRPI0920135A2 (pt) | imidazopiridazinacarbonitrilos úteis como inibidores de quinase | |
BRPI0906973A2 (pt) | Compostos e composições como inibidores de cinase. | |
BRPI0913879A2 (pt) | fenilpirazinonas como inibidores de quinase | |
CO6900140A2 (es) | Compuestos y composiciones como inhibidores de la quinasa c-kit | |
CO6900141A2 (es) | Compuestos y composiciones como inhibidores de la quinasa c-kit | |
BRPI0910979A2 (pt) | compostos e composições como inibidores de quinase | |
BRPI0913580A2 (pt) | pirrolopiridinas como inibidores de quinase | |
SMT201400154B (it) | Composti di triazolopiridina come inibitori di chinasi pim | |
BRPI0912475A2 (pt) | compostos como inibidores de quinase | |
ES2598358T8 (es) | Derivados de quinolina como inhibidores de PI3K quinasa | |
BRPI0811065A2 (pt) | Indazóis 5-heteroaril substituídos como inibidores de quinase | |
BRPI0918846A2 (pt) | inibidores de cinase heterocíclica | |
BRPI0920239A2 (pt) | compostos heterocíclicos como inibidores de proteínas quinases | |
BR112012004448A2 (pt) | "compostos e composições como inibidores de proteína cinase" | |
BRPI0812825A2 (pt) | Derivados ftalazinona como inibidores de parp-1 | |
BRPI0811517A2 (pt) | Compostos e composições como inibidores de c-kit e pdgfr cinase. | |
BRPI0914545A2 (pt) | compostos e composições como inibidores de quinase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2363 DE 19-04-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |